NASDAQ:CNTA

Centessa Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy CNTA

*Your capital is at risk

$39.85

-0.0500 (-0.125%)

At Close: Jun 03, 2026

Centessa Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -59.40. In total, the insiders bought 2.7M and sold 783.2K CNTA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-59.40
● Buy	2.7M shares
● Sell	783.2K shares
60% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence Mar 13, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -59.4. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 01, 2026 Sell	Ordinary Shares F-InKind	Accardi Mario Alberto Chief Executive Officer	CEO / President	604 Value: $23.8K
Mar 26, 2026 Buy	Ordinary Shares M-Exempt	Anderson Karen M. Chief People Officer	Officer	41 076 Value: $329.0K
Mar 26, 2026 Buy	Share Option (right to buy) M-Exempt	Anderson Karen M. Chief People Officer	Officer	41 076 Value: $329.0K
Mar 26, 2026 Sell	Ordinary Shares S-Sale	Anderson Karen M. Chief People Officer	Officer	41 076 Value: $1.24M
Mar 26, 2026 Buy	Ordinary Shares M-Exempt	Weinhoff Gregory M Chief Business Officer	Officer	23 998 Value: $92.4K
Mar 26, 2026 Sell	Ordinary Shares S-Sale	Weinhoff Gregory M Chief Business Officer	Officer	23 998 Value: $719.9K
Mar 26, 2026 Buy	Share Option (right to buy) M-Exempt	Weinhoff Gregory M Chief Business Officer	Officer	23 998 Value: $92.4K
Mar 17, 2026 Sell	Ordinary Shares S-Sale	Anderson Karen M. Chief People Officer	Officer	10 043 Value: $282.2K
Mar 17, 2026 Buy	Ordinary Shares M-Exempt	Anderson Karen M. Chief People Officer	Officer	10 043 Value: $40.3K
Mar 17, 2026 Buy	Share Option (right to buy) M-Exempt	Anderson Karen M. Chief People Officer	Officer	10 043 Value: $40.3K
Mar 16, 2026 Sell	Ordinary Shares S-Sale	Anderson Karen M. Chief People Officer	Officer	64 768 Value: $1.83M
Mar 16, 2026 Buy	Share Option (right to buy) M-Exempt	Anderson Karen M. Chief People Officer	Officer	64 768 Value: $259.7K
Mar 16, 2026 Buy	Ordinary Shares M-Exempt	Anderson Karen M. Chief People Officer	Officer	64 768 Value: $259.7K
Mar 13, 2026 Buy	Ordinary Shares M-Exempt	Anderson Karen M. Chief People Officer	Officer	15 174 Value: $58.4K
Mar 13, 2026 Buy	Ordinary Shares M-Exempt	Anderson Karen M. Chief People Officer	Officer	94 224 Value: $377.8K
Mar 13, 2026 Buy	Share Option (right to buy) M-Exempt	Anderson Karen M. Chief People Officer	Officer	94 224 Value: $377.8K
Mar 13, 2026 Buy	Share Option (right to buy) M-Exempt	Anderson Karen M. Chief People Officer	Officer	15 174 Value: $58.4K
Mar 13, 2026 Sell	Ordinary Shares S-Sale	Weinhoff Gregory M Chief Business Officer	Officer	61 253 Value: $1.60M
Mar 13, 2026 Sell	Ordinary Shares S-Sale	Anderson Karen M. Chief People Officer	Officer	107 961 Value: $2.82M
Mar 13, 2026 Buy	Share Option (right to buy) M-Exempt	Anderson Karen M. Chief People Officer	Officer	109 398 Value: $438.7K
Mar 13, 2026 Buy	Ordinary Shares M-Exempt	Anderson Karen M. Chief People Officer	Officer	109 398 Value: $438.7K
Mar 13, 2026 Sell	Ordinary Shares S-Sale	Anderson Karen M. Chief People Officer	Officer	12 068 Value: $327.4K
Mar 13, 2026 Sell	Ordinary Shares S-Sale	Weinhoff Gregory M Chief Business Officer	Officer	11 943 Value: $324.3K
Feb 02, 2026 Buy	Ordinary Shares A-Award	Anderson Karen M. Chief People Officer	Officer	29 000 Value: $730.5K
Feb 02, 2026 Buy	Share Option (right to buy) A-Award	Anderson Karen M. Chief People Officer	Officer	117 000 Value: $2.95M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CENTESSA PHARMACEUTICALS LIMITED

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatm...

Read Full Profile Here